VIDEO: Update from CheckMate 9ER further shows benefit of nivolumab/cabozantinib in RCC

ByMoshe Ornstein, MD

ByMarley V. Ghizzone

Fact checked byMindy Valcarcel, MS

SAN FRANCISCO — In this video, Moshe Ornstein, MD, highlights findings from the follow-up data of the CheckMate 9ER trial presented at the annual ASCO Genitourinary Cancers Symposium.

The phase 3 trial randomized patients with treatment-naive metastatic renal cell carcinoma to received either nivolumab (Opdivo, Bristol Myers Squibb) plus cabozantinib (Cabometyx, Exelixis) or sunitinib (Sutent, Pfizer) alone, according to the abstract. Patients were followed for a minimum of 25.4 months.

“The median overall survival, which I found really striking, was 49.5 months for patients treated with cabo/nivo versus 35.5 months for patients treated with sunitinib,” Ornstein, genitourinary medical oncologist at Cleveland Clinic Taussig Cancer Institute, said.

Reference:

Burotto M, et al. Abstract 603. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2022; San Francisco.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Ornstein reports serving as a consultant or in an advisory role for Aveo, Bristol Myers Squibb, Eisai, Exelixis, Merck and Pfizer; serving on speakers bureaus for Bristol Myers Squibb and Merck; receiving institutional research funding from Aravive, Astra-Zeneca, Astellas, Bristol Myers Squibb, Merck, Pfizer and Surface Oncology; and receiving reimbursement for travel and accommodations expenses from Bristol Myers Squibb, Eisai, Exelixis and Pfizer.

Take Homes in Renal Cell Carcinoma

Read more

VIDEO: Update from CheckMate 9ER further shows benefit of nivolumab/cabozantinib in RCC

Reference:

Related Content